CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 0: distress zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
327.14MUSDvs all stocks (USD)
Revenue (TTM)
217.78MUSDvs all stocks (USD)
Profit Margin
-109.99%vs Biotechnology peers
Beta
0.6030xvs all stocks
52-Week Change
16.74%vs all stocks
Market Capitalization
327.14MUSDvs all stocks (USD)
Enterprise Value
137.90MUSDvs all stocks (USD)
Forward P/E
27.20xvs Biotechnology peers
Price to Sales (TTM)
1.50xvs Biotechnology peers
Price to Book (MRQ)
1.17xvs Biotechnology peers
Enterprise to Revenue
0.6330xvs Biotechnology peers
Enterprise to EBITDA
-0.9070xvs Biotechnology peers
Gross Margin
93.89%vs Biotechnology peers
Profit Margin
-109.99%vs Biotechnology peers
Operating Margin
-97.11%vs Biotechnology peers
Return on Assets (TTM)
-18.81%vs Biotechnology peers
Return on Equity (TTM)
-60.48%vs Biotechnology peers
Revenue (TTM)
217.78MUSDvs all stocks (USD)
Revenue per Share (TTM)
3.68USDUpdated Jul 19, 2026Quarterly Revenue Growth
3.40%vs Biotechnology peers
Gross Profit (TTM)
205.10MUSDvs all stocks (USD)
EBITDA (TTM)
-151.98MUSDvs all stocks (USD)
Net Income (TTM)
-239.55MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
3.35%vs Biotechnology peers
Operating Cash Flow (TTM)
-126.51MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-83.15MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
216.10MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
13.04MUSDFY2025 · Dec 31, 2025Gross Profit
203.06MUSDFY2025 · Dec 31, 2025Operating Income
-151.17MUSDvs all stocks (USD)
Pre-tax Income
-138.65MUSDFY2025 · Dec 31, 2025Income Tax Expense
81.83MUSDFY2025 · Dec 31, 2025Net Income
-220.47MUSDFY2025 · Dec 31, 2025EBIT
-151.17MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-139.25MUSDFY2025 · Dec 31, 2025Research & Development
109.27MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
237.95MUSDFY2025 · Dec 31, 2025EPS (Basic)
-3.74USDFY2025 · Dec 31, 2025EPS (Diluted)
-3.74USDFY2025 · Dec 31, 2025Basic Shares Outstanding
58.93MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
58.93MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-220.47MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-95.32MUSDFY2025 · Dec 31, 2025Free Cash Flow
-96.32MUSDDerived from operating cash flow minus capital expenditure. This filing charges 11.92M of depreciation against 998K of capital expenditure, and its own free-cash-flow line reads -110.44M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
85.32MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-220.47MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.92MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
81.44MUSDFY2025 · Dec 31, 2025Stock-based Compensation
9.47MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.94MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-7.46MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
15.82MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
12.02MUSDFY2025 · Dec 31, 2025Capital Expenditures
-998.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-112.38MUSDFY2025 · Dec 31, 2025Sale of Investments
208.24MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
94.86MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
-1.99MUSDFY2025 · Dec 31, 2025Other Financing Charges
-915.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-2.91MUSDFY2025 · Dec 31, 2025Shares Outstanding
60.14MSharesUpdated Jul 19, 2026Float Shares
53.84MSharesUpdated Jul 19, 2026Shares Short
7.34MSharesUpdated Jul 19, 2026Short Ratio
7.93daysvs all stocks
Short % of Shares Outstanding
12.82%vs all stocks
% Held by Insiders
6.65%vs all stocks
% Held by Institutions
78.73%vs all stocks
Total Cash (MRQ)
202.31MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
3.36USDUpdated Jul 19, 2026Total Debt (MRQ)
13.07MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0466xvs Biotechnology peers
Current Ratio (MRQ)
2.16xvs Biotechnology peers
Book Value per Share (MRQ)
4.67USDUpdated Jul 19, 2026Total Assets
488.95MUSDvs all stocks (USD)
Total Current Assets
347.26MUSDFY2025 · Dec 31, 2025Total Liabilities
161.76MUSDFY2025 · Dec 31, 2025Total Non-current Assets
141.69MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
16.60MUSDFY2025 · Dec 31, 2025Total Current Liabilities
145.16MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
84.85MUSDFY2025 · Dec 31, 2025Other Short-term Investments
179.00MUSDFY2025 · Dec 31, 2025Accounts Receivable
54.58MUSDFY2025 · Dec 31, 2025Inventory
1.85MUSDFY2025 · Dec 31, 2025Accounts Payable
4.94MUSDFY2025 · Dec 31, 2025Short-term Debt
5.55MUSDFY2025 · Dec 31, 2025Long-term Debt
7.07MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
9.53MUSDFY2025 · Dec 31, 2025Common Stock (Book)
59.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-394.77MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
327.19MUSDvs all stocks (USD)
52-Week Low
4.14USDUpdated Jul 19, 202652-Week High
9.94USDUpdated Jul 19, 202652-Week Change
16.74%vs all stocks
Beta
0.6030xvs all stocks
50-Day MA
6.15USDUpdated Jul 19, 2026200-Day MA
6.53USDUpdated Jul 19, 2026Avg 10-Day Volume
869.26KSharesUpdated Jul 19, 2026Avg 30-Day Volume
901.90KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-4.06USDUpdated Jul 19, 2026Other Income / Expense
12.52MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.94Profit Margin: -1.10
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 2.16Altman Z-Score: 0.00
Financial Health
Altman Z-Score 0: distress zoneCritical
Altman Z-Score: 0.00
High earnings qualityNotable
Earnings Quality Score: 0.71
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Hubei Guangji Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Inhibikase Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanxi C&Y Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shapuaisi Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tellgen Corporation
Tier 1ProductionApproval-Gated PipelineRule
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule